| Literature DB >> 31698781 |
Doyeon Kim1, Abdullah M Assiri1,2, Ji Heui Kim1.
Abstract
This study aimed to identify trends in bacteria isolated from Korean adults with chronic rhinosinusitis (CRS). Enrolled were CRS patients who underwent sinus bacterial culture during endoscopic sinus surgery between 2007-2008, 2011-2012, and 2017-2018 (n = 510). Patients' clinical characteristics, bacterial culture results, and antibiotic resistance were reviewed. The bacteria isolation rate was 76.3% (73.9% for CRS with nasal polyps and 82.8% for CRS without nasal polyps; p = 0.038). In total, 650 strains were isolated, the most common was Coagulase Negative Staphylococci (CNS) (28.0%), followed by Streptococcus species (12.2%), Propionibacterium species (8.0%), Corynebacterium species (7.5%), Staphylococcus aureus (6.2%), Haemophilus species (5.7%), Klebsiella species (5.1%), and Pseudomonas aeruginosa (4.2%). Furthermore, an analysis of the bacterial trends in the three groups showed significant increases over time for the isolation of CNS (p = 0.006), Klebsiella (p = 0.002), and P. aeruginosa (p = 0.007) and extended-spectrum beta-lactamase (ESBL) producing Klebsiella (p < 0.001) and Enterobacter (p = 0.007) species in terms of antibiotics resistance. This study demonstrates that the frequency of CNS, Klebsiella, and P. aeruginosa in CRS patients and the ESBL-producing Klebsiella and Enterobacter species has significantly increased in CRS patients over the last decade.Entities:
Keywords: bacteria; chronic rhinosinusitis; culture; endoscopic sinus surgery; microbiology; swab
Year: 2019 PMID: 31698781 PMCID: PMC6912634 DOI: 10.3390/jcm8111889
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Comparison of age and sex distribution according to the culture results.
| Variable | Bacterial Culture | ||
|---|---|---|---|
| Positive | Negative | ||
| Age (years), mean ± S.D. | 47.2 ± 17.0 | 46.9 ± 16.7 | 0.889 |
| Male gender, number (%) | 237 (60.9) | 75 (62.0) | 0.835 |
Comparison of bacterial isolation rate according to the demographic data.
| Nasal Polyp | Atopy | Asthma | Current Smoker | |||||
|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | Yes | No | |
| No. of patients | 376 | 134 | 51 | 459 | 33 | 477 | 87 | 423 |
| Isolation rate, % | 73.9 | 82.8 | 66.7 | 77.3 | 72.7 | 76.5 | 75.9 | 76.4 |
| 0.038 | 0.089 | 0.625 | 0.921 | |||||
Number and percentage of bacterial isolates (n = 650 strains).
| Isolated Bacteria [ | |||
|---|---|---|---|
| Total Isolates | CRSsNP | CRSwNP | |
|
| |||
| Coagulase negative | 182 (28.0%) | 55 (28.1%) | 127 (28.0%) |
| | 159 (24.5%) | 45 (23.0%) | 114 (25.1%) |
| Others | 23 (3.5%) | 10 (5.1%) | 13 (2.9%) |
| | 79 (12.2%) | 32 (16.3%) | 47 (10.4%) |
| | 30 (4.6%) | 6 (3.1%) | 24 (5.3%) |
| | 22 (3.4%) | 14 (7.1%) | 8 (1.8%) |
| | 12 (1.8%) | 5 (2.6%) | 7 (1.5%) |
| | 6 (0.9%) | 3 (1.5%) | 3 (0.6%) |
| | 5 (0.8%) | 4 (2.0%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 49 (7.5%) | 6 (3.1%) | 43 (9.5%) |
| | 40 (6.2%) | 10 (5.1%) | 30 (6.6%) |
| | 21 (3.2%) | 13 (6.6%) | 8 (1.8%) |
| | 18 (2.8%) | 2 (1.0%) | 16 (3.5%) |
| Others | |||
| | 7 (1.1%) | 2 (1.0%) | 5 (1.1%) |
| | 4 (0.6%) | 0 (0.0%) | 4 (0.9%) |
| | 2 (0.3%) | 1 (0.5%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
|
| |||
| | 52 (8.0%) | 10 (5.1%) | 42 (9.3%) |
| | 3 (0.5%) | 1 (0.5%) | 2 (0.4%) |
|
| |||
| | 37 (5.7%) | 6 (3.1%) | 31 (6.8%) |
| | 33 (5.1%) | 6 (3.1%) | 27 (5.9%) |
| Others | 4 (0.6%) | 0 (0.0%) | 4 (0.9%) |
| | 33 (5.1%) | 7 (3.6%) | 26 (5.7%) |
| | 16 (2.5%) | 3 (1.5%) | 13 (2.9%) |
| | 13 (2.0%) | 3 (1.5%) | 10 (2.2%) |
| | 4 (0.6%) | 1 (0.5%) | 3 (0.7%) |
| | 28 (4.3%) | 9 (4.6%) | 19 (4.2%) |
| | 6 (0.9%) | 0 (0.0%) | 6 (1.3%) |
| Others | |||
| | 3 (0.5%) | 3 (1.5%) | 0 (0.0%) |
| | 3 (0.5%) | 1 (0.5%) | 2 (0.4%) |
| | 2 (0.3%) | 1 (0.5%) | 1 (0.2%) |
| | 2 (0.3%) | 1 (0.5%) | 1 (0.2%) |
| | 2 (0.3%) | 1 (0.5%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 1 (0.5%) | 0 (0.0%) |
|
| |||
| | 27 (4.2%) | 14 (7.1%) | 13 (2.9%) |
| | 5 (0.8%) | 2 (1.0%) | 3 (0.7%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
| | 1 (0.2%) | 1 (0.5%) | 0 (0.0%) |
|
| |||
| | 17 (2.6%) | 11 (5.6%) | 6 (1.3%) |
| | 4 (0.6%) | 4 (2.0%) | 0 (0.0%) |
| | 2 (0.3%) | 2 (1.0%) | 0 (0.0%) |
| | 1 (0.2%) | 0 (0.0%) | 1 (0.2%) |
CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps.
Comparison of the isolated bacteria in patients with non-eosinophilic and eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) between October 2017 and December 2018.
| Organisms | Eosinophilic CRSwNP | Non-eosinophilic CRSwNP | |
|---|---|---|---|
|
| 46.0 | 26.0 | 0.003 |
| 8.0 | 16.0 | 0.082 | |
| 12.9 | 0.0 | <0.001 | |
|
| 8.0 | 5.0 | 0.390 |
| 0.0 | 10.9 | 0.001 | |
| 21.0 | 37.0 | 0.013 | |
| 4.0 | 0.0 | 0.043 | |
|
| 0.0 | 5.0 | 0.024 |
Trends of frequently cultured bacteria over time.
| Organisms | 2007–2008 | 2012–2013 | 2017–2018 | |
|---|---|---|---|---|
| CNS | 21.5 | 29.4 | 33.3 | 0.006 |
| 11.2 | 10.0 | 15.3 | 0.196 | |
| 12.1 | 11.8 | 0.0 | <0.001 | |
| 11.2 | 7.6 | 3.7 | 0.003 | |
|
| 8.1 | 4.3 | 6.0 | 0.364 |
| 5.8 | 3.8 | 7.4 | 0.484 | |
| 4.0 | 0.5 | 10.6 | 0.002 | |
| 6.3 | 2.8 | 3.7 | 0.181 | |
|
| 2.7 | 1.9 | 7.9 | 0.007 |
Trends in the antibiotic resistance of frequently cultured bacteria over time.
| Organism | 2007–2008 | 2012–2013 | 2017–2018 | |
|---|---|---|---|---|
| Amoxicillin/clavulanate | 0 (0.0%) | 0 (0.0%) | 2 (0.9%) | 0.082 |
| Macrolide a | 8 (3.6%) | 10 (4.7%) | 13 (6.0%) | 0.233 |
|
| ||||
| Methicillin | 2 (0.9%) | 1 (0.5%) | 2 (0.9%) | 0.977 |
| Ampicillin | 8 (34.8%) | 1 (0.5%) | 10 (4.6%) | 0.532 |
| ESBL | 1 (0.4%) | 1 (0.5%) | 16 (7.4%) | <0.001 |
| Ciprofloxacin | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) | 0.229 |
| ESBL | 0 (0.0%) | 6 (2.8%) | 8 (3.7%) | 0.007 |
| Ciprofloxacin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | N/A |
|
| ||||
| ESBL | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | N/A |
| Ciprofloxacin | 0 (0.0%) | 0 (0.0%) | 2 (0.9%) | 0.082 |
N/A, not available; ESBL, extended-spectrum beta-lactamase; a Macrolide includes azithromycin, erythromycin, and clarithromycin.